Recent data suggest that inflammatory bowel disease (IBD) patients do not receive
preventive services at the same rate as general medical patients. Patients with IBD often …

The treatment of inflammatory bowel disease (IBD) has been revolutionised over the past
decade by the increasing use of immunomodulators, mainly azathioprine (AZA)/6 …

Background & Aim Patients with inflammatory bowel diseases (IBD), specifically those
treated with anti–tumor necrosis factor (TNF) α biologics, are at high risk for vaccine …

An international panel of experts prepared an evidenced-based guideline for vaccination of
immunocompromised adults and children. These guidelines are intended for use by primary …

Canada has among the highest rates of childhood-onset IBD in the world. Over 7000
children and youth under 18 years old are living with IBD in Canada, and 600 to 650 …

OBJECTIVES: Patients with inflammatory bowel disease (IBD) may be at increased risk for
infections. We aimed to determine the pneumonia risk in IBD and how specific medications …

Background Since immunomodulators and antitumor necrosis factor (TNF) agents are
increasingly used to treat inflammatory bowel disease (IBD), it is recommended to …

Patients with immune-mediated inflammatory diseases (IMID) such as RA, IBD or psoriasis,
are at increased risk of infection, partially because of the disease itself, but mostly because …

OBJECTIVES: The treatment of inflammatory bowel disease (IBD) often includes
immunosuppressive medications, which may increase the risk of vaccine-preventable …

Background Vedolizumab specifically recognises the α4β7 integrin and selectively blocks
gut lymphocyte trafficking: potentially, it offers gut‐specific immunosuppression. Aim To …